Plain-English translation of NCT05583708 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combined with can help people with merkel cell cancer whose cancer has progressed despite previous immunotherapy treatment. is a radioactive therapy that targets cancer cells with specific receptors, while is an immunotherapy drug that helps your immune system fight cancer. The study will look at how safe this combination is and whether it can slow or stop the cancer from growing.
Merkel cell cancer is a rare and aggressive skin cancer, and many patients' tumors stop responding to standard immunotherapy alone. This trial explores whether adding a targeted radioactive treatment alongside the immunotherapy might help people whose cancer has already stopped responding to other treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive four doses of the radioactive treatment () spaced two months apart, and you will continue receiving the immunotherapy drug () every six weeks for up to two years. You will have regular clinic visits for blood tests, imaging scans, and check-ins to monitor how well the treatment is working and watch for any side effects. The study runs for approximately two years, but you can stop earlier if your cancer progresses or if you experience side effects that are too difficult to manage.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States